You are here

  • Home
  • Archive
  • Volume 7, Issue Suppl 1
  • O-9 Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients

Article metrics

Article menu

Download PDFPDF

Oral Presentations
O-9 Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients
Free

 

Online download statistics by month:

Online download statistics by month: March 2017 to March 2024

AbstractFullPdf
Mar 2017200
Apr 201742020
May 201729015
Jun 20171801
Jul 20172202
Aug 20173106
Sep 20174409
Oct 20174204
Nov 20174504
Dec 20178402
Jan 201810202
Feb 201810009
Mar 2018114014
Apr 20184600
May 20185004
Jun 20182404
Jul 20182001
Aug 20182402
Sep 20181201
Oct 20182803
Nov 20186800
Dec 20187001
Jan 20193601
Feb 20193300
Mar 20192309
Apr 2019306
May 2019204
Jun 20192904
Jul 2019605
Aug 2019602
Sep 2019601
Oct 2019602
Nov 2019702
Dec 2019801
Jan 2020200
Feb 2020602
Mar 2020203
Apr 2020201
May 2020801
Jun 2020403
Jul 2020601
Aug 2020002
Sep 20202003
Oct 2020803
Nov 20201301
Dec 2020801
Jan 2021502
Feb 2021408
Mar 2021302
Apr 2021002
May 20211003
Jun 2021002
Jul 2021003
Aug 2021001
Sep 2021003
Oct 20218016
Nov 20217016
Dec 2021200
Jan 2022902
Feb 20221201
Mar 2022401
Apr 20222001
May 202214014
Jun 20221406
Jul 20221102
Aug 20221903
Sep 202213010
Oct 2022704
Nov 2022806
Dec 20221501
Jan 2023803
Feb 2023200
Mar 2023800
Apr 2023202
May 2023704
Jun 2023900
Jul 2023204
Aug 2023006
Sep 2023902
Oct 2023002
Nov 2023602
Dec 2023600
Jan 2024600
Feb 2024203
Mar 20247049
Total15200348